

## PRODUCT INFORMATION

<b>Clone ID</b>	DMC219
<b>Target</b>	FCGR3A
<b>Synonyms</b>	FCGR3A;CD16A;FCG3;FCGR3;IGFR3
<b>Host Species</b>	Rabbit
<b>Description</b>	Biotinylated Anti-FCGR3A antibody(DMC219); IgG1 Chimeric mAb
<b>Delivery</b>	2-3 weeks
<b>Uniprot ID</b>	P08637
<b>IgG type</b>	Rabbit/Human Fc chimeric IgG1
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	Human
<b>Applications</b>	ELISA; Flow Cyt
<b>Recommended Dilutions</b>	ELISA 1:5000-10000; Flow Cyt 1:100
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Storage &amp; Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	This gene encodes a receptor for the Fc portion of immunoglobulin G; and it is involved in the removal of antigen-antibody complexes from the circulation; as well as other other antibody-dependent responses. This gene (FCGR3A) is highly similar to another nearby gene (FCGR3B) located on chromosome 1. The receptor encoded by this gene is expressed on natural killer (NK) cells as an integral membrane glycoprotein anchored through a transmembrane peptide; whereas FCGR3B is expressed on polymorphonuclear neutrophils (PMN) where the receptor is anchored through a phosphatidylinositol (PI) linkage. Mutations in this gene have been linked to susceptibility to recurrent viral infections; susceptibility to systemic lupus erythematosus; and alloimmune neonatal neutropenia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
<b>Usage</b>	Research use only
<b>Conjugate</b>	Biotinylated
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

